Gene editing partnership reaches new in vivo success
Scribe Therapeutics reported a second in vivo success milestone with partner Eli Lilly for CRISPR-based therapies targeting neurological and neuromuscular diseases. The company highlighted its epigenetic silencing program STX-1150 (PCSK9) aimed at lowering LDL, with a planned clinic entry in mid-2026.
Why it mattersSTX-1150's planned mid-2026 clinic entry and Lilly validation should prompt investors to reassess genetic-medicine allocations.
Entities Mentioned
Scribe TherapeuticsEli Lilly